Mapez is a pyridylbenzodiazepine compound with anxiolytic properties. In low dosage, it diminishes anxiety, tension and nervousness. In high dosage, the sedative and muscle-relaxant properties appear.

Mapez is indicated in the following diseases

Emotional disturbances: Anxiety and tension states, as adjuvant therapy for anxiety in depression patients, nervous tension, restlessness and anxiety and tension related insomnia. As an adjuvant to treatment of underlying disease responsible for functional or psychosomatic impairments of various organs caused by anxiety and tension.

Cardiovascular and respiratory systems: Pseudoangina pectoris, precordial; anxiety, tachycardia, emotiogenic hypertension, dyspnea and hyperventilation.

Gastrointestinal tract: Irritable bowel syndrome, ulcerative colitis, epigastric pain, spasm, meteorism and diarrhoea.

Urogenital tract: Irritable bladder, urinary frequency and dysmenorrhea.

Other psychosomatic disturbances: Psychogenic headache, psychogenic dermatoses.

Mapez is suitable for treatment of anxiety and tension states due to chronic organic disease and as an adjuvant to psychotherapy in psychoneurosis.

Adults: The optimum dosage and frequency of administration of Bromazepam is based on the individual patient, the severity of symptoms and previous psychotropic drug history.

Average dose for outpatient therapy: 1.5-3 mg 3 times daily.

Severe cases, especially in hospitals: 6-12 mg 2-3 times daily.

Treatment  of outpatients should begin with low doses, gradually increasing to the optimum level, in general, the total duration of treatment should  not exceed 8-12 weeks including a tapering-off period. In certain cases, treatment may need to be continued beyond the maximum recommended duration but only after a careful reassessment of the patient’s condition and indications.

Elderly patients: Doses should not exceed half those normally recommended.

Children: Bromazepam is not for paediatric use.

Common side-effects include drowsiness, sedation, unsteadiness and ataxia. These are dose-related and may persist into the following day, even after a single dose. Other side effects are rare and include headache, vertigo, hypotension, gastrointestinal upsets, skin rashes, visual disturbances and urinary retention. 

In patients with chronic pulmonary insufficiency and in patients with chronic renal or hepatic disease, dosage may need to be reduced.

Bromazepam should not be used alone to treat depression or anxiety associated with depression.

Bromazepam should be used with extreme caution in patients with a history of alcohol or drug abuse.

Bromazeparn is contraindicated in patients with known hypersensitivity to benzodiazepines; severe respiratory failure, sleep apnea syndrome, myasthenia gravis and severe liver failure.

If Bromazepam is combined with other centrally acting drugs, such as neuroleptics, tranquilizers, antidepressants, hypnotics, narcotic analgesics and anesthetics, its CNS sedation effect may be increased.

Bromazepam tablets should be stored in cool and dry place, protected from light and moisture